Condition
Immune Modulation
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
75% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06747143Not ApplicableCompletedPrimary
Short-term Immunomodulatory Effects of Lactobacillus Casei DN-114001: Impacts on Gut Microbiota Composition and Systemic Immune Biomarkers in Healthy Adults
NCT03084614TerminatedPrimary
CD8 Reactivity to Microorganisms in Blood and Breast Milk
NCT01200836Completed
Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol
NCT02025660Phase 2Completed
Efficacy of Mw Vaccine in Treatment of Severe Sepsis
Showing all 4 trials